Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-12-03

Clinical Trial Update: Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating the ease of use and safety of the U300 insulin pen injector in insulin-naïve adults with Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TOUJEO (insulin glargine)

Snippet

Sponsor: Sanofi | Conditions: Diabetes Mellitus Type 2 | Phase 3 | Status: COMPLETED